Nuno Marques
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nuno Marques has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Dina Bento
Cardiology Department, Hospital de Faro, Unidade Local de Saúde do Algarve, Portugal
3 shared publicationsIlídio Jesus
Department of Cardiology Centro Hospitalar Universitário do Algarve–Hospital de Faro Faro 8000-386 Portugal
2 shared publicationsOlga Azevedo
Cardiology Department, Hospital Senhora da Oliveira, Guimarães, Portugal
2 shared publications- Olga Azevedo
Cardiology Department, Hospital da Senhora da Oliveira, Guimarães, Portugal (O.A.).
2 shared publications - Ana Gomes Almeida
Department of Cardiology, Unidade Local de Saúde de Santa Maria, (ULSSM), CAML, CCUL@RISE, Faculdade de Medicina, Universidade de Lisboa , Lisboa
1 shared publication Ana Rita Almeida
Cardiology Department Hospital Garcia de Orta Almada Portugal
1 shared publication
Latest Publications
- Open Access
- 14 February 2025
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 44, 3-5
Portuguese recommendations on transthyretin amyloid cardiomyopathy: A step toward disease awareness, prompt referral and early diagnosis and treatment
- 14 February 2025
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 44, 3-5
Open AccessPortuguese recommendations on transthyretin amyloid cardiomyopathy: A step toward disease awareness, prompt referral and early diagnosis and treatment
- Open Access
- 14 February 2025
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 44, 7-48
Portuguese recommendations for the management of transthyretin amyloid cardiomyopathy (Part 1 of 2): Screening, diagnosis and treatment. Developed by the Task Force on the management of transthyretin amyloid cardiomyopathy of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology
- 14 February 2025
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 44, 7-48
Open AccessPortuguese recommendations for the management of transthyretin amyloid cardiomyopathy (Part 1 of 2): Screening, diagnosis and treatment. Developed by the Task Force on the management of transthyretin amyloid cardiomyopathy of the Working Group on Myocardial and Pericardial Diseases of the Portuguese Society of Cardiology
- Open Access
- 15 August 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (8) , 1263
Charting the Path: Navigating Embryonic Development to Potentially Safeguard against Congenital Heart Defects
Congenital heart diseases (CHDs) are structural or functional defects present at birth due to improper heart development. Current therapeutic approaches to treating severe CHDs are primarily palliative surgical interventions during the peri- or prenatal stages, when the heart has fully developed from faulty embryogenesis. However, earlier interventions during embryonic development have the potential for better outcomes, as demonstrated by fetal cardiac interventions performed in utero, which have shown improved neonatal and prenatal survival rates, as well as reduced lifelong morbidity. Extensive research on heart development has identified key steps, cellular players, and the intricate network of signaling pathways and transcription factors governing cardiogenesis. Additionally, some reports have indicated that certain adverse genetic and environmental conditions leading to heart malformations and embryonic death may be amendable through the activation of alternative mechanisms. This review first highlights key molecular and cellular processes involved in heart development. Subsequently, it explores the potential for future therapeutic strategies, targeting early embryonic stages, to prevent CHDs, through the delivery of biomolecules or exosomes to compensate for faulty cardiogenic mechanisms. Implementing such non-surgical interventions during early gestation may offer a prophylactic approach toward reducing the occurrence and severity of CHDs.
- 15 August 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (8) , 1263
Open AccessCharting the Path: Navigating Embryonic Development to Potentially Safeguard against Congenital Heart Defects
Congenital heart diseases (CHDs) are structural or functional defects present at birth due to improper heart development. Current therapeutic approaches to treating severe CHDs are primarily palliative surgical interventions during the peri- or prenatal stages, when the heart has fully developed from faulty embryogenesis. However, earlier interventions during embryonic development have the potential for better outcomes, as demonstrated by fetal cardiac interventions performed in utero, which have shown improved neonatal and prenatal survival rates, as well as reduced lifelong morbidity. Extensive research on heart development has identified key steps, cellular players, and the intricate network of signaling pathways and transcription factors governing cardiogenesis. Additionally, some reports have indicated that certain adverse genetic and environmental conditions leading to heart malformations and embryonic death may be amendable through the activation of alternative mechanisms. This review first highlights key molecular and cellular processes involved in heart development. Subsequently, it explores the potential for future therapeutic strategies, targeting early embryonic stages, to prevent CHDs, through the delivery of biomolecules or exosomes to compensate for faulty cardiogenic mechanisms. Implementing such non-surgical interventions during early gestation may offer a prophylactic approach toward reducing the occurrence and severity of CHDs.
- 25 January 2023
- Published by Taylor & Francis in Future Cardiology
- Vol. 19 (1) , 39-43
Challenges in Fabry Disease: the Combination of Two Individually Amenable GLA Variants May Be Nonamenable to Migalastat
Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, resulting in reduced or absent α-Gal A activity. Migalastat is an oral chaperone therapy for Fabry patients w... Plain language summary Fabry disease is a rare genetic disease that is part of a group of conditions called lysosomal storage diseases. It is characterized by an abnormal accumulation of glycosphin...
- 25 January 2023
- Published by Taylor & Francis in Future Cardiology
- Vol. 19 (1) , 39-43
Challenges in Fabry Disease: the Combination of Two Individually Amenable GLA Variants May Be Nonamenable to Migalastat
Fabry disease is a rare lysosomal storage disorder caused by mutations in the GLA gene, resulting in reduced or absent α-Gal A activity. Migalastat is an oral chaperone therapy for Fabry patients w... Plain language summary Fabry disease is a rare genetic disease that is part of a group of conditions called lysosomal storage diseases. It is characterized by an abnormal accumulation of glycosphin...
- Open Access
- 8 February 2022
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 41 (3) , 261-262
Left ventricular non-compaction: Challenges in the etiopathogenesis and risk stratification of sudden cardiac death in clinical practice
- 8 February 2022
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 41 (3) , 261-262
Open AccessLeft ventricular non-compaction: Challenges in the etiopathogenesis and risk stratification of sudden cardiac death in clinical practice
- Open Access
- 6 October 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (19)
Specific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence‐Based Recommendations
Background: The emergence of specific therapies for transthyretin cardiac amyloidosis (CA) warrants the need for a systematic review of the literature. Methods and Results: A systematic review of the literature was conducted according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. A systematic search was performed on MEDLINE, PubMed, and Embase databases on November 29, 2019. Studies were selected based on the following predefined eligibility criteria: English‐language randomized controlled trials (RCTs), non‐RCTs, or observational studies, which included adult patients with variant/wild‐type transthyretin‐CA, assessed specific therapies for transthyretin‐CA, and reported cardiovascular outcomes. Relevant data were extracted to a predefined template. Quality assessment was based on National Institute for Health and Care Excellence recommendations (RCTs) or a checklist by Downs and Black (non‐RCTs). From 1203 records, 24 publications were selected, describing 4 RCTs (6 publications) and 16 non‐RCTs (18 publications). Tafamidis was shown to significantly improve all‐cause mortality and cardiovascular hospitalizations and reduce worsening in 6‐minute walk test, Kansas City Cardiomyopathy Questionnaire—Overall Summary score, and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) in variant/wild‐type transthyretin‐CA. Patisiran showed promising results in a subgroup analysis of patients with variant transthyretin‐CA, which have to be confirmed in RCTs. Inotersen showed conflicting results on cardiac imaging parameters. The one study on AG10 had only a 1‐month duration and cardiovascular end points were exploratory and limited to cardiac biomarkers. Limited evidence from noncomparative single‐arm small non‐RCTs existed for diflunisal, epigallocatechin‐3‐gallate (green tea extract), and doxycycline+tauroursodeoxycholic acid/ursodeoxycholic acid. Conclusions: This systematic review of the literature supports the use of tafamidis in wild‐type and variant transthyretin‐CA. Novel therapeutic targets including transthyretin gene silencers are currently under investigation.
- 6 October 2020
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 9 (19)
Open AccessSpecific Therapy for Transthyretin Cardiac Amyloidosis: A Systematic Literature Review and Evidence‐Based Recommendations
Background: The emergence of specific therapies for transthyretin cardiac amyloidosis (CA) warrants the need for a systematic review of the literature. Methods and Results: A systematic review of the literature was conducted according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) guidelines. A systematic search was performed on MEDLINE, PubMed, and Embase databases on November 29, 2019. Studies were selected based on the following predefined eligibility criteria: English‐language randomized controlled trials (RCTs), non‐RCTs, or observational studies, which included adult patients with variant/wild‐type transthyretin‐CA, assessed specific therapies for transthyretin‐CA, and reported cardiovascular outcomes. Relevant data were extracted to a predefined template. Quality assessment was based on National Institute for Health and Care Excellence recommendations (RCTs) or a checklist by Downs and Black (non‐RCTs). From 1203 records, 24 publications were selected, describing 4 RCTs (6 publications) and 16 non‐RCTs (18 publications). Tafamidis was shown to significantly improve all‐cause mortality and cardiovascular hospitalizations and reduce worsening in 6‐minute walk test, Kansas City Cardiomyopathy Questionnaire—Overall Summary score, and NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) in variant/wild‐type transthyretin‐CA. Patisiran showed promising results in a subgroup analysis of patients with variant transthyretin‐CA, which have to be confirmed in RCTs. Inotersen showed conflicting results on cardiac imaging parameters. The one study on AG10 had only a 1‐month duration and cardiovascular end points were exploratory and limited to cardiac biomarkers. Limited evidence from noncomparative single‐arm small non‐RCTs existed for diflunisal, epigallocatechin‐3‐gallate (green tea extract), and doxycycline+tauroursodeoxycholic acid/ursodeoxycholic acid. Conclusions: This systematic review of the literature supports the use of tafamidis in wild‐type and variant transthyretin‐CA. Novel therapeutic targets including transthyretin gene silencers are currently under investigation.
- Open Access
- 1 April 2019
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 38 (4) , 267-268
Longitudinal strain by speckle tracking echocardiography: Is it useful in clinical practice for differentiating Takotsubo syndrome from anterior myocardial infarction?
- 1 April 2019
- Published by Elsevier in Revista Portuguesa de Cardiologia (English Edition)
- Vol. 38 (4) , 267-268
Open AccessLongitudinal strain by speckle tracking echocardiography: Is it useful in clinical practice for differentiating Takotsubo syndrome from anterior myocardial infarction?
- Open Access
- 1 April 2019
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 38 (4) , 267-268
Longitudinal strain by speckle tracking echocardiography: Is it useful in clinical practice for differentiating Takotsubo syndrome from anterior myocardial infarction?
- 1 April 2019
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 38 (4) , 267-268
Open AccessLongitudinal strain by speckle tracking echocardiography: Is it useful in clinical practice for differentiating Takotsubo syndrome from anterior myocardial infarction?
- Open Access
- 2 June 2013
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 7 (1) , 150
A 72-year-old woman with an uncorrected tetralogy of Fallot presenting with possible pulmonary endocarditis: a case report
Tetralogy of Fallot is one of the most common forms of cyanotic congenital heart disease and in the absence of surgical correction it has an elevated early mortality, with most patients dying in childhood.
- 2 June 2013
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 7 (1) , 150
Open AccessA 72-year-old woman with an uncorrected tetralogy of Fallot presenting with possible pulmonary endocarditis: a case report
Tetralogy of Fallot is one of the most common forms of cyanotic congenital heart disease and in the absence of surgical correction it has an elevated early mortality, with most patients dying in childhood.
- Open Access
- 1 October 2012
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 31 (10) , 647-654
Impacto da via verde coronária e da angioplastia primária na redução da mortalidade associada ao enfarte com elevação do segmento ST anterior. A experiência algarvia
- 1 October 2012
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 31 (10) , 647-654
Open AccessImpacto da via verde coronária e da angioplastia primária na redução da mortalidade associada ao enfarte com elevação do segmento ST anterior. A experiência algarvia